Latest Search
Quote
| Back Zoom + Zoom - | ||||
|
HENLIUS (02696.HK) HLX11 Marketing Application Approved by European Commission
Recommend 0 Positive 0 Negative 0 |
||||
|
||||
|
HENLIUS (02696.HK) announced that the marketing authorization application for its self-developed POHERDY?(pertuzumab) 420mg/14mL injection has been approved by the European Commission. The approval signifies that POHERDY?has obtained centralized marketing authorization in all European Union member states as well as Iceland, Liechtenstein and Norway. The approved indications cover all indications of the reference pertuzumab that have been authorized in Europe. (de/d) This article was automatically translated by AI, the Chinese version should be considered the authoritative version. AASTOCKS.com Limited does not guarantee its accuracy or completeness and accepts no liability for any damages or losses arising from the use of this translation. Auto-translated by AI AASTOCKS Financial News |
||||
Copied to Clipboard
 |
||||
